After more than three decades of work and almost US$1 billion of investment, GlaxoSmithKline Plc and its partners are ready to deploy a vaccine for malaria, the mosquito-borne disease that kills almost half a million people each year.[LONDON] After more than three decades of work and almost US$1 billion of investment, GlaxoSmithKline Plc and its partners are ready to deploy a vaccine for malaria, the mosquito-borne disease that kills almost half a million people each year.
"Mobilising funding for these major endeavors which do not have a commercial opportunity has been a challenge, and will be an even bigger challenge in the future," said Thomas Breuer, chief medical officer of Glaxo's vaccines unit.UK drugmaker Glaxo, which estimates it's spending more than US$700 million on the project, would like to"hand over the funding baton to others," according to Breuer.
"A vaccine that is highly efficacious - 90 per cent or so - that's not in view at this point," she said."But this vaccine getting to where it is shows that a malaria vaccine can be made. It will be a pathfinder."The effort underscores the challenge of developing products for poorer countries that carry costs extending well beyond clinical trials and approvals, said Ashley Birkett, director of PATH's Malaria Vaccine Initiative.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »